Novel organic proteasome inhibitors identified by virtual and in vitro screening

J Med Chem. 2010 Jan 14;53(1):509-13. doi: 10.1021/jm9011092.

Abstract

Proteasome inhibition is a promising strategy for treating cancers. Herein, we report the discovery of novel drug-like inhibitors of mammalian proteasome 20S using a multistep structure-based virtual ligand screening strategy. Sulfone- or piperazine-containing hits essentially belong to the under-represented class of noncovalent and nonpeptidic proteasome inhibitors. Several of our compounds act in the micromolar range and are cytotoxic on human tumoral cell lines. Optimization of these molecules could lead to better anticancer therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antineoplastic Agents / chemical synthesis
  • Antineoplastic Agents / chemistry
  • Antineoplastic Agents / pharmacology*
  • Antineoplastic Agents / toxicity
  • Cell Line
  • Cell Proliferation / drug effects
  • Crystallography, X-Ray
  • Databases, Factual
  • Drug Discovery*
  • Drug Screening Assays, Antitumor
  • HeLa Cells
  • Humans
  • Models, Molecular
  • Molecular Structure
  • Piperazine
  • Piperazines / chemical synthesis
  • Piperazines / chemistry
  • Piperazines / pharmacology*
  • Piperazines / toxicity
  • Protease Inhibitors / chemical synthesis
  • Protease Inhibitors / chemistry
  • Protease Inhibitors / pharmacology*
  • Protease Inhibitors / toxicity
  • Proteasome Inhibitors*
  • Rabbits
  • Stereoisomerism
  • Structure-Activity Relationship
  • Sulfones / chemical synthesis
  • Sulfones / chemistry
  • Sulfones / pharmacology*
  • Sulfones / toxicity

Substances

  • Antineoplastic Agents
  • Piperazines
  • Protease Inhibitors
  • Proteasome Inhibitors
  • Sulfones
  • Piperazine